Genetics in MedicineGenetic & Genomic MedicinePeer-reviewed journal article
Quantitative longitudinal natural history of eight gangliosidoses - conceptual framework and baseline data of the German 8-in-1 disease registry. A cross-sectional analysis.
Markus RiesiD, Grecia Mendoza, Laila Arash‐Kaps, Yasmina AmraouiiD, Folker Quack, Brigitte Hardt, Stefan DiederichiD, Michael BeckiD, Karl Eugen MengeliD
Abstract
PurposeGangliosidoses are a group of inherited neurogenetic autosomal recessive lysosomal storage disorders usually presenting with progressive macrocephaly, developmental delay and regression, leading to significant morbidity, and premature death. A quantitative definition of the natural history would support and enable clinical development of specific therapies. MethodsSingle disease registry of eight gangliosidoses (NCT04624789). Cross-sectional analysis of baseline data in N= 26 patients. Primary endpoint: disease severity assessed by the 8-in-1 score. Secondary endpoints: first neurological sign or symptom observed a. by parents and b. by physicians, diagnostic delay, as well as phenotypical characterization. Tertiary endpoints: Neurological outcomes (development, ataxia, dexterity) and disability. ResultsThe 8-in-1 score quantitatively captured severity of disease. Parents recognized initial manifestations (startle reactions) earlier than physicians (motor developmental delay and hypotonia). Median diagnostic delay was 3.16 [IQR 0.69 ... 6.25] years. Eight patients presented with late-infantile phenotypes. ConclusionData in this registry raise awareness of these rare and fatal conditions in order to accelerate diagnosis, inform counselling of afflicted families, define quantitative endpoints for clinical trials, and can serve as historical controls for future therapeutic studies. The characterization of a late-infantile phenotype is novel. Longitudinal follow-up is planned.
- organism: human
- research focus: database / resource
- research focus: benchmarking
- approach: experimental assay
- Citations
- 5
- FWCI
- 0.31
- Field percentile
- top 45%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- GM1 Gangliosidosis Type II: Results of a 10-Year Prospective Study
Precilla D’Souza, Cristan Farmer, … Cynthia J. Tifft·Genetics in MedicinePeer-reviewed·Apr 16, 2024
- NGLY1 Deficiency: A Prospective Natural History Study (NHS)
Sandra Tong-Starksen, Pamela E. Ventola, … Kevin J. Lee·Human Molecular GeneticsPeer-reviewed·Jun 25, 2023
- Expanding the phenotype spectrum of β-mannosidosis
Angela M. Martin Rios, Karolina M. Stępień, … Virginia E. Kimonis·Neurology GeneticsPeer-reviewed·Nov 7, 2025
- Linking Enzyme Upregulation to Autophagic Failure: A Potential Biomarker for GM1 Gangliosidosis
- Characterization of Glycosylphosphatidylinositol Biosynthesis Defects by Clinical Features, Flow Cytometry, and Automated Image Analysis
Alexej Knaus, Jean Tori Pantel, … Peter Michael Krawitz·Genome MedicinePeer-reviewed·Jan 5, 2018
- AAV9 Gene Therapy in GM1 Gangliosidosis Type II: A Phase 1/2 Trial
Connor J. Lewis, Precilla D’Souza, … Cynthia J. Tifft·New England Journal of MedicinePeer-reviewed·Feb 6, 2026